Prevention and Treatment of Monkeypox

Overview

Journal Drugs

Specialty Pharmacology

Date 2022 Jun 28

PMID 35763248

Authors

John G Rizk

Giuseppe Lippi

Brandon M Henry

Donald N Forthal

Youssef Rizk

Affiliations

Soon will be listed here.

Abstract

Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, and via fomites such as towels and bedding. Multiple medical countermeasures are stockpiled for orthopoxviruses such as monkeypox. Two vaccines are currently available, JYNNEOS (live, replication incompetent vaccinia virus) and ACAM2000 (live, replication competent vaccinia virus). While most cases of monkeypox will have mild and self-limited disease, with supportive care being typically sufficient, antivirals (e.g. tecovirimat, brincidofovir, cidofovir) and vaccinia immune globulin intravenous (VIGIV) are available as treatments. Antivirals can be considered in severe disease, immunocompromised patients, pediatrics, pregnant and breastfeeding women, complicated lesions, and when lesions appear near the mouth, eyes, and genitals. The purpose of this short review is to describe each of these countermeasures.

Citing Articles

Inpatient Management of Monkeypox.

Shaw Z, Selvaraj V, Finn A, Lorenz M, Santos M, Dapaah-Afriyie K Brown J Hosp Med. 2025; 1(3):37605.

PMID: 40046598 PMC: 11878817. DOI: 10.56305/001c.37605.

A review of epidemiology, diagnosis, and management of Mpox: The role of One Health.

Huang C, Su S, Chen K Glob Health Med. 2025; 7(1):1-12.

PMID: 40026855 PMC: 11866911. DOI: 10.35772/ghm.2024.01072.

Repurposing doxycycline for the inhibition of monkeypox virus DNA polymerase: a comprehensive computational study.

Yousaf M, Michel M, Khan A, Noreen M, Bano S In Silico Pharmacol. 2025; 13(1):27.

PMID: 39958784 PMC: 11825436. DOI: 10.1007/s40203-025-00307-7.

Elucidating the Mechanism of VVTT Infection Through Machine Learning and Transcriptome Analysis.

Chen Z, Jiang Y, Cui J, Li W, Han W, Liu G Int J Mol Sci. 2025; 26(3).

PMID: 39940969 PMC: 11818747. DOI: 10.3390/ijms26031203.

Mpox: Global epidemic situation and countermeasures.

Hou W, Wu N, Liu Y, Tang Y, Quan Q, Luo Y Virulence. 2025; 16(1):2457958.

PMID: 39921615 PMC: 11810083. DOI: 10.1080/21505594.2025.2457958.

References

Hammarlund E, Lewis M, Carter S, Amanna I, Hansen S, Strelow L . Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med. 2005; 11(9):1005-11. DOI: 10.1038/nm1273. View

Baker R, Bray M, Huggins J . Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003; 57(1-2):13-23. PMC: 9533837. DOI: 10.1016/s0166-3542(02)00196-1. View

Grosenbach D, Honeychurch K, Rose E, Chinsangaram J, Frimm A, Maiti B . Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med. 2018; 379(1):44-53. PMC: 6086581. DOI: 10.1056/NEJMoa1705688. View

Fine P, Jezek Z, GRAB B, Dixon H . The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988; 17(3):643-50. DOI: 10.1093/ije/17.3.643. View

Petersen B, Harms T, Reynolds M, Harrison L . Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses - Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep. 2016; 65(10):257-62. DOI: 10.15585/mmwr.mm6510a2. View

Yang Z . Monkeypox: A potential global threat?. J Med Virol. 2022; 94(9):4034-4036. PMC: 9283296. DOI: 10.1002/jmv.27884. View

Smee D . Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008; 19(3):115-24. DOI: 10.1177/095632020801900302. View

Wittek R . Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis. 2006; 10(3):193-201. DOI: 10.1016/j.ijid.2005.12.001. View

Adler H, Gould S, Hine P, Snell L, Wong W, Houlihan C . Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022; 22(8):1153-1162. PMC: 9300470. DOI: 10.1016/S1473-3099(22)00228-6. View

10.

Guarner J, Del Rio C, Malani P . Monkeypox in 2022-What Clinicians Need to Know. JAMA. 2022; 328(2):139-140. DOI: 10.1001/jama.2022.10802. View

11.

Reynolds M, McCollum A, Nguete B, Shongo Lushima R, Petersen B . Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research. Viruses. 2017; 9(12). PMC: 5744154. DOI: 10.3390/v9120380. View

12.

Realegeno S, Puschnik A, Kumar A, Goldsmith C, Burgado J, Sambhara S . Monkeypox Virus Host Factor Screen Using Haploid Cells Identifies Essential Role of GARP Complex in Extracellular Virus Formation. J Virol. 2017; 91(11). PMC: 5432867. DOI: 10.1128/JVI.00011-17. View

13.

Parker S, Chen N, Foster S, Hartzler H, Hembrador E, Hruby D . Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox. Antiviral Res. 2012; 94(1):44-53. PMC: 3722602. DOI: 10.1016/j.antiviral.2012.02.005. View

14.

Heymann D, Szczeniowski M, Esteves K . Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. 1999; 54(3):693-702. DOI: 10.1093/oxfordjournals.bmb.a011720. View

15.

Vora S, Damon I, Fulginiti V, Weber S, Kahana M, Stein S . Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis. 2008; 46(10):1555-61. DOI: 10.1086/587668. View

16.

Nalca A, Rimoin A, Bavari S, Whitehouse C . Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis. 2005; 41(12):1765-71. DOI: 10.1086/498155. View

17.

Quenelle D, Buller R, Parker S, Keith K, Hruby D, Jordan R . Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2006; 51(2):689-95. PMC: 1797744. DOI: 10.1128/AAC.00879-06. View

18.

Chittick G, Morrison M, Brundage T, Nichols W . Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. Antiviral Res. 2017; 143:269-277. DOI: 10.1016/j.antiviral.2017.01.009. View

19.

Crum-Cianflone N, Sullivan E . Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I. Infect Dis Ther. 2017; 6(3):303-331. PMC: 5595780. DOI: 10.1007/s40121-017-0166-x. View

20.

Lanier R, Trost L, Tippin T, Lampert B, Robertson A, Foster S . Development of CMX001 for the Treatment of Poxvirus Infections. Viruses. 2011; 2(12):2740-2762. PMC: 3077800. DOI: 10.3390/v2122740. View